Storaktionærmeddelse
July 15, 2016 09:55 ET
|
Zealand Pharma A/S
København, 15. juli 2016 – Zealand meddeleler, at selskabet har modtaget en storaktionærmeddelelse fra Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 København Ø (CVR-nr. 33 85 91 98)....
Major shareholder announcement
July 15, 2016 09:55 ET
|
Zealand Pharma A/S
Copenhagen, 15 July 2016 – Zealand informs that the company has received a major shareholder announcement from Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 Copenhagen (CVR no. 33 85 91 98)....
Zealand tildeler warrants under medarbejder-warrantprogram
July 15, 2016 05:23 ET
|
Zealand Pharma A/S
København, 15. juli 2016 - Zealand meddeler at have tildelt warrants til ét medlem af selskabets ledelse. Tildelingen af warrants sker under warrantprogrammet, der er dækket af bemyndigelsen i § 8.4...
Zealand grants new warrants under employee warrant program
July 15, 2016 05:23 ET
|
Zealand Pharma A/S
Copenhagen, 15 July 2016 - Zealand announces the grant of warrants to a member of the company’s senior management. The warrants are granted under the warrant program covered by the authority...
Zealand meddeler det samlede antal aktier og stemmerettigheder i selskabet pr. 30. juni 2016
June 30, 2016 06:14 ET
|
Zealand Pharma A/S
København, 30. juni 2016 – I henhold til § 6 i Bekendtgørelse om udsteders oplysningsforpligtelser udsender Zealand meddelelser med information om det samlede antal aktier og stemmerettigheder i...
Zealand announces the total number of shares and voting rights in the company as of 30 June 2016
June 30, 2016 06:14 ET
|
Zealand Pharma A/S
Copenhagen, 30 June 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to inform of the total number of shares and...
Zealand increases its share capital as a consequence of exercise of employee warrants
June 16, 2016 06:52 ET
|
Zealand Pharma A/S
Copenhagen, 16 June 2016 – Zealand has increased its share capital with nominal DKK 41,269 divided into 41,269 new shares with a nominal value of DKK 1 each. The increase is a consequence of the...
Zealand forhøjer aktiekapitalen som følge af udnyttelse af medarbejderwarrants
June 16, 2016 06:52 ET
|
Zealand Pharma A/S
København, 16. juni 2016 – Zealand meddeler at have forhøjet sin aktiekapital med nominelt 41.269 kr. fordelt på 41.269 nye aktier à nominelt 1 kr. Forhøjelsen er sket som følge af, at der er sket...
Positive results from pivotal Phase III clinical trials with iGlarLixi presented at the American Diabetes Association 76th Scientific Sessions
June 12, 2016 15:46 ET
|
Zealand Pharma A/S
Type 2 diabetes patients treated with iGlarLixi (formerly LixiLan) had significantly greater reductions in blood glucose (HbA1c) versus treatment with either lixisenatide or Lantus®...
Positive resultater fra kliniske fase III-studier med iGlarLixi er blevet præsenteret på den 76. amerikanske diabeteskongres (ADA)
June 12, 2016 15:46 ET
|
Zealand Pharma A/S
Type 2-diabetikere behandlet med iGlarLixi (tidligere benævnt LixiLan), opnåede en signifikant større sænkning af deres langtidsblodsukker (HBA1c) i forhold til behandling med enten lixisenatid...